(Reuters) -Eli Lilly ( LLY ) hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.

Here are some reactions to Lilly joining the trillion dollar club:

EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS

"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."

HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST

"Investors have historically liked secure earnings growth and (Eli Lilly ( LLY )) is the only large cap pharma that has that kind of earnings profile."